Relay Therapeutics (RLAY) Total Non-Current Liabilities (2020 - 2024)

Relay Therapeutics (RLAY) has 5 years of Total Non-Current Liabilities data on file, last reported at $93.5 million in Q4 2024.

• Total Non-Current Liabilities for Q4 2024 came in at $93.5 million, up 18.7% year-over-year; the trailing twelve-month figure through Dec 2024 was $93.5 million (up 18.7% YoY), and the FY2024 annual result was $93.5 million, up 18.7% from the prior year.
• Total Non-Current Liabilities improved to $93.5 million in Q4 2024 per RLAY's latest filing, from $90.8 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $126.0 million in Q3 2022 and troughed at $36.5 million in Q4 2020.
• A 5-year average of $83.8 million and a median of $84.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities soared 151.74% in 2022, then plunged 32.77% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $36.5 million in 2020, then soared by 65.25% to $60.4 million in 2021, then soared by 94.07% to $117.2 million in 2022, then sank by 32.77% to $78.8 million in 2023, then grew by 18.7% to $93.5 million in 2024.
• Business Quant data shows RLAY's Total Non-Current Liabilities at $93.5 million in Q4 2024, $90.8 million in Q2 2024, and $84.3 million in Q1 2024.